Adynxx is a clinical-stage biopharmaceutical company focused on bringing to market novel therapeutics for the treatment of pain and inflammatory diseases. A leader in transcription factor decoy technology, Adynxx is utilizing its platform of AYX transcription factor decoys to create first-in-class therapies with disease-modifying properties. Transcription factor decoys are short, synthetic double-stranded DNA oligonucleotides that bind to transcription factors and prevent their interaction with the genome, effectively inhibiting a coordinated network of pathologic gene expression. The AYX platform has applications across multiple disease states and has initially been leveraged to create novel, non-opioid therapeutics for the treatment of pain.
Company profile
Ticker
ADYX
Exchange
Website
CEO
Rick Orr
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Alliqua BioMedical, Inc., Alliqua, Inc., Hepalife Technologies Inc, Zeta Corp, Zeta Corp
SEC CIK
Corporate docs
IRS number
582349413
ADYX stock data
Latest filings (excl ownership)
15-12B
Securities registration termination
20 Mar 20
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Mar 20
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Mar 20
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Mar 20
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Mar 20
RW
Registration withdrawal request
20 Mar 20
8-K
Unregistered Sales of Equity Securities
17 Dec 19
S-1/A
IPO registration (amended)
14 Nov 19
10-Q
2019 Q3
Quarterly report
14 Nov 19
8-K
Adynxx Reports Third Quarter 2019 Financial Results
14 Nov 19
Latest ownership filings
3
GREGORY J. FLESHER
29 Jul 19
3
AquaMed Technologies, Inc.
21 Jun 19
3
DINA GONZALEZ
11 Jun 19
SC 13D/A
Alliqua BioMedical, Inc.
14 May 19
3
DAVID BONDERMAN
13 May 19
3
JAMES C BLAIR
13 May 19
3
JAMES C BLAIR
13 May 19
SC 13D
Alliqua BioMedical, Inc.
13 May 19
4
STAN E ABEL
7 May 19
4
ECKARD WEBER
7 May 19
Institutional ownership, Q2 2022
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|